A novel activating mutation in the RET tyrosine kinase domain mediates neoplastic transformation

Molecular Endocrinology

Volumn 20, Issue 7, 2006, Pages 1633-1643

  Cranston, Aaron ^a   Carniti, Cristiana ^b   Martin, Sam ^a   Mondellini, Piera ^b   Hooks, Yvette ^a   Leyland, Jean ^a   Hodgson, Shirley ^c   Clarke, Sue ^c   Pierotti, Marco ^b   Ponder, Bruce A J ^a   Bongarzone, Italia ^b  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b NATIONAL CANCER INSTITUTE   (Italy)

^c GUY S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYSTEINE; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; PROTEIN RET; PROTEIN TYROSINE KINASE;

ADULT; AMINO ACID SUBSTITUTION; ANAMNESIS; ARTICLE; BASEMENT MEMBRANE; BLOOD SAMPLING; CANCER INVASION; CARCINOGENESIS; CASE REPORT; CELL TRANSFORMATION; CODON; DIMERIZATION; DNA EXTRACTION; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME PHOSPHORYLATION; ENZYME SUBSTRATE; EXON; FEMALE; GENE MUTATION; GENE SEQUENCE; HUMAN; IN VITRO STUDY; IN VIVO STUDY; METASTASIS; MISSENSE MUTATION; PHENOTYPE; PRIORITY JOURNAL; PROTO ONCOGENE; RNA SPLICING; THYROID CARCINOMA; THYROIDECTOMY;

ANIMALS; CELL TRANSFORMATION, NEOPLASTIC; CYSTEINE; DIMERIZATION; FEMALE; GENE EXPRESSION REGULATION; HUMANS; MICE; MIDDLE AGED; MUTATION, MISSENSE; NEOPLASM INVASIVENESS; NIH 3T3 CELLS; PROTEIN STRUCTURE, TERTIARY; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS C-RET; UP-REGULATION;

EID: 33745660334     PISSN: 08888809     EISSN: 08888809     Source Type: Journal    
DOI: 10.1210/me.2004-0447     Document Type: Article

References (46)

1. Takahashi M 2001 The GDNF/RET signaling pathway and human diseases. Cytokine Growth Factor Rev 12:361-373
2. Pachnis V, Mankoo B, Costantini F 1993 Expression of the c-ret proto-oncogene during mouse embryogenesis. Development 119:1005-1017
3. Edery P, Eng C, Munnich A, Lyonnet S 1997 RET in human development and oncogenesis. Bioessays 19:389-395
4. Ponder BA, Smith D 1996 The MEN II syndromes and the role of the ret proto-oncogene. Adv Cancer Res 70:179-222
5. Eng C, Mulligan LM 1997 Mutations of the RET protooncogene in the multiple endocrine neoplasia type 2 syndromes, related sporadic tumours, and hirschsprung disease. Hum Mutat 9:97-109
6. Eng C 1999 RET proto-oncogene in the development of human cancer. J Clin Oncol 17:380-393
7. Ponder BA 1999 The phenotypes associated with ret mutations in the multiple endocrine neoplasia type 2 syndrome. Cancer Res 59(Suppl):1736-1741
8. Santoro M, Carlomagno F, Melillo RM, Billaud M, Vecchio G, Fusco AJ 1999 Molecular mechanisms of RET activation in human neoplasia. Endocrinol Invest 22:811-819
9. Hansford JR, Mulligan LM 2000 Multiple endocrine neoplasia type 2 and RET: from neoplasia to neurogenesis. J Med Genet 37:817-827
10. Jhiang SM 2000 The RET proto-oncogene in human cancers. Oncogene 19:5590-5597
11. Asai N, Iwashita T, Matsuyama M, Takahashi M 1995 Mechanism of activation of the ret proto-oncogene by multiple endocrine neoplasia 2A mutations. Mol Cell Biol 15:1613-1619
12. Santoro M, Carlomagno F, Romano A, Bottaro DP, Dathan NA, Grieco M, Fusco A, Vecchio G, Matoskova B, Kraus MH, Di Fiore PP 1995 Activation of RET as a dominant transforming gene by germline mutations of MEN2A and MEN2B. Science 267:381-383
13. Carlson KM, Dou S, Chi D, Scavarda N, Toshima K, Jackson CE, Wells Jr SA, Goodfellow PJ, Donis-Keller H 1994 Single missense mutation in the tyrosine kinase catalytic domain of the RET protooncogene is associated with multiple endocrine neoplasia type 2B. Proc Natl Acad Sci USA 91:1579-1583
14. Hofstra RM, Landsvater RM, Ceccherini I, Stulp RP, Stelwagen T, Luo Y, Pasini B, Hoppener JW, van Amstel HK, Romeo G, Lips CJM, Buys CHCM 1994 A mutation in the RET proto-oncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma. Nature 367:375-376
15. Smith DP, Houghton C, Ponder BA 1997 Germline mutation of RET codon 883 in two cases of de novo MEN 2B. Oncogene 15:1213-1217
16. Gimm O, Marsh DJ, Andrew SD, Frilling A, Dahia PL, Mulligan LM, Zajac JD, Robinson BG, Eng C 1997 Germline dinucleotide mutation in codon 883 of the RET protooncogene in multiple endocrine neoplasia type 2B without codon 918 mutation. J Clin Endocrinol Metab 82:3902-3904
17. Eng C, Mulligan LM, Smith DP, Healey CS, Frilling A, Raue F, Neumann HP, Ponder MA, Ponder BA 1995 Low frequency of germline mutations in the RET proto-oncogene in patients with apparently sporadic medullary thyroid carcinoma. Clin Endocrinol 43:123-127
18. Wohllk N, Cote GJ, Bugalho MM, Ordonez N, Evans DB, Goepfert H, Khorana S, Schultz P, Richards CS, Gagel RF 1996 Relevance of RET proto-oncogene mutations in sporadic medullary thyroid carcinoma. J Clin Endocrinol Metab 81:3740-3745
19. Schuffenecker I, Virally-Monod M, Brohet R, Goldgar D, Conte-Devolx B, Leclerc L, Chabre O, Boneu A, Caron J, Houdent C, Modigliani E, Rohmer V, Schlumberger M, Eng C, Guillausseau PJ, Lenoir GM 1998 Risk and penetrance of primary hyperparathyroidism in multiple endocrine neoplasia type 2A families with mutations at codon 634 of the RET proto-oncogene. J Clin Endocrinol Metab 83:487-491
20. Scurini C, Quadro L, Fattoruso O, Verga U, Libroia A, Lupoli G, Cascone E, Marzano L, Paracchi S, Busnardo B, Girelli ME, Bellastella A, Colantuoni V 1998 Germline and somatic mutations of the RET proto-oncogene in apparently sporadic medullary thyroid carcinomas. Mol Cell Endocrinol 137:51-57
21. Donis-Keller H, Dou S, Chi D, Carlson KM, Toshima K, Lairmore TC, Howe JR, Moley JF, Goodfellow P, Wells Jr SA 1993 Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC. Hum Mol Genet 2:851-856
22. Zedenius J, Wallin G, Hamberger B, Nordenskjold M, Weber G, Larsson C 1994 Somatic and MEN 2A de novo mutations identified in the RET proto-oncogene by screening of sporadic MTCs. Hum Mol Genet 3:1259-1262
23. Eng C, Mulligan LM, Smith DP, Healey CS, Frilling A, Raue F, Neumann HP, Pfragner R, Behmel A, Lorenzo MJ, Stonehouse TJ, Ponder MA, Ponder BAJP 1995 Mutation of the RET protooncogene in sporadic medullary thyroid carcinoma. Genes Chromosomes Cancer 12:209-212
24. Jhiang SM, Fithian L, Weghorst CM, Clark OH, Falko JM, O'Dorisio TM, Mazzaferri EL 1996 RET mutation screening in MEN2 patients and discovery of a novel mutation in a sporadic medullary thyroid carcinoma. Thyroid 6:115-121
25. Marsh DJ, Andrew SD, Learoyd DL, Pojer R, Eng C, Robinson BG 1998 Deletion-insertion mutation encompassing RET codon 634 is associated with medullary thyroid carcinoma. Human Mutation 1(Suppl):3-4
26. Eng C, Smith DP, Mulligan LM, Healey CS, Zvelebil MJ, Stonehouse TJ, Ponder MA, Jackson CE, Waterfield MD, Ponder BA 1995 A novel point mutation in the tyrosine kinase domain of the RET proto-oncogene in sporadic medullary thyroid carcinoma and in a family with FMTC. Oncogene 10:509-513
27. Marsh DJ, McDowall D, Hyland VJ, Andrew SD, Schnitzler M, Gaskin EL, Nevell DF, Diamond T, Delbridge L, Clifton-Bligh P, Robinson BG 1996 The identification of false positive responses to the pentagastrin stimulation test in RET mutation negative members of MEN 2A families. Clin Endocrinol 44:213-220
28. Gimm O, Neuberg DS, Marsh DJ, Dahia PL, Hoang-Vu C, Raue F, Hinze R, Dralle H, Eng C 1999 Over-representation of a germline RET sequence variant in patients with sporadic medullary thyroid carcinoma and somatic RET codon 918 mutation. Oncogene 18:1369-1373
29. van der Geer P, Hunter T, Lindberg RA 1994 Receptor protein-tyrosine kinases and their signal transduction pathways. Annu Rev Cell Biol 10:251-337
30. Iwashita T, Kato M, Murakami H, Asai N, Ishiguro Y, Ito S, Iwata Y, Kawai K, Asai M, Kurokawa K, Kajita H, Takahashi M 1999 Biological and biochemical properties of Ret with kinase domain mutations identified in multiple endocrine neoplasia type 2B and familial medullary thyroid carcinoma. Oncogene 18:3919-3922
31. Bongarzone I, Vigano E, Alberti L, Borrello MG, Pasini B, Greco A, Mondellini P, Smith DP, Ponder BA, Romeo G, Pierotti MA 1998 Full activation of MEN2B mutant RET by an additional MEN2A mutation or by ligand GDNF stimulation. Oncogene 16:2295-2301
32. Heldin CH 1995 Dimerization of cell surface receptors in signal transduction Cell 80:213-223
33. Ishiguro Y, Iwashita T, Murakami H, Asai N, Iida K, Goto H, Hayakawa T, Takahashi M 1999 The role of amino acids surrounding tyrosine 1062 in ret in specific binding of the shc phosphotyrosine-binding domain. Endocrinology 140:3992-3998
34. Iwashita T, Murakami H, Kurokawa K, Kawai K, Miyauchi A, Futami H, Qiao S, Ichihara M, Takahashi M 2000 A two-hit model for development of multiple endocrine neoplasia type 2B by RET mutations. Biochem Biophys Res Commun 268:804-808
35. Pasini A, Geneste O, Legrand P, Schlumberger M, Rossel M, Fournier L, Rudkin BB, Schuffenecker I, Lenoir GM, Billaud M 1997 Oncogenic activation of RET by two distinct FMTC mutations affecting the tyrosine kinase domain. Oncogene 15:393-402
36. Fink M, Weinhusel A, Niederle B, Haas OA 1996 Distinction between sporadic and hereditary medullary thyroid carcinoma (MTC) by mutation analysis of the RET proto-oncogene Study Group Multiple Endocrine Neoplasia Austria (SMENA). Int J Can 69:312-316
37. Kato M, Iwashita T, Akhand AA, Liu W, Takeda K, Takeuchi K, Yoshihara M, Hossain K, Wu J, Du J, Oh C, Kawamoto Y, Suzuki H, Takahashi M, Nakashima I 2000 Molecular mechanism of activation and superactivation of Ret tyrosine kinases by ultraviolet light irradiation. Antioxid Redox Signal 2:841-849
38. Takeda K, Kato M, Wu J, Iwashita T, Suzuki H, Takahashi M, Nakashima I 2001 Osmotic stress-mediated activation of RET kinases involves intracellular disulfide-bonded dimer formation. Antioxid Redox Signal 3:473-482
39. Carlomagno F, Vitagliano D, Guida T, Napolitano M, Vecchio G, Fusco A, Gazit A, Levitzki A, Santoro M 2002 The kinase inhibitor PP1 blocks tumorigenesis induced by RET oncogenes. Cancer Res 62:1077-1082
40. Carlomagno F, Vitagliano D, Guida T, Ciardiello F, Tortora G, Vecchio G, Ryan AJ, Fontanini G, Fusco A, Santoro M 2002 ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases. Cancer Res 62:7284-7290
41. Cohen MS, Hussain HB, Moley JF 2002 Inhibition of medullary thyroid carcinoma cell proliferation and RET phosphorylation by tyrosine kinase inhibitors. Surgery 132:960-966
42. Sawyer TK, Bohacek RS, Dalgarno DC, Eyermann CJ, Kawahata N, Metcalf III CA, Shakespeare WC, Sundaramoorthi R, Wang Y, Yang MG 2002 SRC homology-2 inhibitors: peptidomimetic and nonpeptide. Mini Rev Med Chem 2:475-488
43. Carniti C, Perego C, Mondellini P, Pierotti MA, Bongarzone I 2003 PP1 inhibitor induces degradation of RETMEN2A and RETMEN2B oncoproteins through proteosomal targeting. Cancer Res 63:2234-2243
44. Bongarzone I, Monzini N, Borrello MG, Carcano C, Ferraresi G, Arighi E, Mondellini P, Della Porta G, Pierotti MA 1993 Molecular characterization of a thyroid tumor-specific transforming sequence formed by the fusion of ret tyrosine kinase and the regulatory subunit RI α of cyclic AMP-dependent protein kinase A. Mol Cell Biol 13:358-366
45. Borrello MG, Pelicci G, Arighi E, De Filippis L, Greco A, Bongarzone I, Rizzetti M, Pelicci PG, Pierotti MA 1994 The oncogenic versions of the Ret and Trk tyrosine kinases bind Shc and Grb2 adaptor proteins. Oncogene 9:1661-1668
46. Bongarzone I, Vigano E, Alberti L, Mondellini P, Uggeri M, Pasini B, Borrello, MG, Pierotti MA 1999 The Glu632-Leu633 deletion in cysteine rich domain of Ret induces constitutive dimerization and alters the processing of the receptor protein. Oncogene 18:4833-4838